Literature DB >> 18689275

Tacrolimus (FK506) associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in lung transplant salvage with a plasmapheresis and cyclosporin.

Fouad N Boctor1.   

Abstract

Thrombotic microangiopathy (TMA), a microvascular hemolytic disorder is a rare, but well described complication in organ transplant patients receiving immunosuppressant drugs. We report a 56-year-old female with a history of left lung transplant that presented to the hospital with microangiopathic hemolytic anemia and thrombocytopenia while receiving tacrolimus (FK 506) for 36 months. The patient was diagnosed with tacrolimus-induced TTP/HUS and started on daily plasmapheresis, and replacement of FK506 with cyclosporine. After thirteen plasmapheresis procedures, her platelet count, lactate dehydrogenase, and hematocrit were normalized. The ADAMTS-13 activity was subnormal and no inhibitory antibody was detected. The combination of daily plasmapheresis with fresh frozen plasma as a source of ADAMTS-13 and cyclosporine may be used as a rescue therapy in patients with FK506-induced TTP/HUS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18689275

Source DB:  PubMed          Journal:  Egypt J Immunol


  3 in total

1.  Dangerous drug interactions leading to hemolytic uremic syndrome following lung transplantation.

Authors:  Haralabos Parissis; Kate Gould; John Dark
Journal:  J Cardiothorac Surg       Date:  2010-09-02       Impact factor: 1.637

Review 2.  Hematologic abnormalities following renal transplantation.

Authors:  Mark A Marinella
Journal:  Int Urol Nephrol       Date:  2009-03-20       Impact factor: 2.266

3.  Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.

Authors:  P Dalal; G Shah; D Chhabra; Lorenzo Gallon
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.